My Top 4 Stocks to Buy in Early 2026

Alphabet and Nvidia offer investors a smart way to get exposure to the AI wave. AbbVie and Interactive Brokers can prove to be resilient long-term picks.

The Motley Fool • 3 hours ago

The Smartest Dividend Stocks to Buy in 2026 With $1,000 Right Now -- Including Realty Income and AbbVie

Dividend-paying stocks can be great for investors of any age. The income they deliver can be invested in more shares of stock.

The Motley Fool • Jan 19, 2026

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

AbbVie has increased its dividend by 333% since 2013. Coca-Cola is a Dividend King that still has plenty of growth potential.

The Motley Fool • Jan 19, 2026

The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever

Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie's immunosuppressant portfolio helps it to produce steady revenue and profits.

The Motley Fool • Jan 19, 2026

Could Buying This Stock Today Pay Off Big Over the Next 5 Years?

AbbVie's core products have ample growth potential over the next five years. The company also won't face a significant patent cliff in the near future.

The Motley Fool • Jan 18, 2026

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to improve the survival rate in patients in a late-stage study.

Reuters • Jan 16, 2026

AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large institutions frequently use the options market to place high-conviction bets before major news becomes public.

MarketBeat • Jan 16, 2026

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

PRNewsWire • Jan 16, 2026

AbbVie (ABBV) Stock Dips While Market Gains: Key Facts

AbbVie (ABBV) reached $216.75 at the closing of the latest trading day, reflecting a -2.32% change compared to its last close.

Zacks Investment Research • Jan 15, 2026

3 Absurdly Cheap Growth Stocks to Buy in 2026

These stocks trade at forward earnings multiples of less than 16, well below the S&P 500 average. What's more, their longer-term price-to-earnings-growth ratios are attractive at less than 1.

The Motley Fool • Jan 15, 2026